SK Bioscience is reportedly sealing the deal on commercializing four types of GSK vaccines in South Korea.

When the deal is finalized, SK Bioscience would be able to fill the gap of four types of MSD vaccinea taken over by HK inno.N last year.

According to a pharmaceutical industry source on Jan. 5, SK Bioscience and GSK Korea are in discussion for co-promotion contracts on a cervical cancer vaccine Cervarix, a hepatitis A virus vaccine Havrix, a meningococcal vaccine Menveo, and a Tdap vaccine Boostrix.

SK Bioscience and GSK Korea left no official comments, but the industry seems to be aware that the two companies are close to inking the co-promotion deal.